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A B S T R A C T
Peptide YY(3-36) ((PYY(3-36)) and glucagon like peptide 1 (GLP-1) in combination reduce food intake and body
weight in an additive or synergistic manner in animal models and in humans. Nevertheless, the mechanisms
behind are not completely understood. The present study aims to investigate the eﬀect of combining PYY(3-36)
and the GLP-1 receptor agonist exendin-4 (Ex4) by examining acute food intake and global neuronal activation
as measured by c-fos in C57BL/6 J mice. An additive reduction in food intake was found 1.5 h after s.c dosing
with the combination of PYY(3-36) (200 μg/kg) and Ex4 (2.5 μg/kg). This was associated with a synergistic
enhancement of c-fos reactivity in central amygdalar nucleus (CeA), rostral part of the mediobasal arcuate
nucleus (ARH), supratrigeminal nucleus (SUT), lateral parabrachial nucleus (PB), area postrema (AP) and nu-
cleus tractus solitarius (NTS) compared to vehicle, PYY(3-36) and Ex4 individually dosed mice. The regions
activated by Ex4 individually and PYY(3-36) and Ex4 in combination resembled each other, but the combination
group had a signiﬁcantly stronger c-fos response. Twenty-ﬁve brain areas were activated by PYY(3-36) and Ex4
in combination compared to vehicle versus nine brain areas by Ex4 individually. No signiﬁcant increase in c-fos
reactivity was found by PYY(3-36) compared to vehicle dosed mice. The neuronal activation of ARH and the AP/
NTS to PB to CeA pathway is important for appetite regulation while SUT has not previously been reported in the
regulation of energy balance. As PYY(3-36) and Ex4 act on diﬀerent neurons leading to recruitment of diﬀerent
signalling pathways within and to the brain, an interaction of these pathways may contribute to their additive/
synergistic action. Thus, PYY(3-36) boosts the eﬀect of Ex4 possibly by inducing less inhibition of neuronal
activity leading to an enhanced neuronal activity induced by Ex4.
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1. Introduction
PYY and GLP-1 are gut hormones co-secreted from intestinal L-cells
into the circulatory system following a meal to mediate post-prandial
satiety. In humans, studies with PYY(3-36) and GLP-1 analogues in
combination have shown additive or synergistic eﬀect on food intake
(Neary et al., 2005; De Silva et al., 2011; Schmidt et al., 2014). In ro-
dent models, treatment with PYY(3-36) and GLP-1 analogues in com-
bination has shown promising synergistic eﬀects on blood glucose
regulation, food intake and body weight reduction (Talsania et al.,
2005; Fenske et al., 2012; Reidelberger et al., 2011). To date, no studies
have provided evidence of the underlying mechanism of the synergism
between PYY(3-36) and GLP-1 on the eﬀect on food intake and body
weight reduction. The energy homeostasis is tightly regulated by the
central nervous system that integrates signals from the peripheral and
central brain regions (Schwartz, 2006; Huo et al., 2009; Sohn et al.,
2013). PYY(3-36) has a high aﬃnity for NPY subtype 2 receptors (Y2)
and GLP-1 eﬀectively binds to the GLP-1 receptor (GLP-1R), and both
receptors are widely expressed in the vagus nerve (Koda et al., 2005;
Ritter, 2004; Nakagawa et al., 2004; Egerod et al., 2018) and the brain
(Jensen et al., 2018; Broberger et al., 1997; Stanic et al., 2006; Parker &
Herzog, 1999). It is likely that the synergistic eﬀect of PYY(3-36) and
GLP-1 is mediated through vagus nerve and appetite-regulating neurons
in hypothalamus and hindbrain interacting with each other to supress
food intake. The present study investigate the additive/synergistic ef-
fect of PYY(3-36) and Ex4 by examining the acute c-fos signal in brain
areas in lean C57BL/6J mice. c-fos is a neuronal activity marker giving
information of activated brain areas within 30–60min after treatment
(Morgan & Curran, 1991). Identifying and understanding the mechan-
isms leading to the additive/synergistic eﬀect of PYY(3-36) and GLP-1
could potentially contribute to a treatment with increased eﬃcacy in
patients with obesity and diabetes.
2. Methodology
2.1. Experimental animals
The experimental procedures in the present study were approved by
the Animal Experiments Inspectorate (2005/561-989), under Danish
Ministry of Justice, and are in accordance with the Danish Animal
Experimentations Act. The study was performed at the Laboratory
Animal Unit at Novo Nordisk A/S, Måløv, Denmark.
2.2. Study design
The present paper included two mice studies. Study I aimed to in-
vestigate the acute additive/synergistic eﬀect of PYY(3-36) and Ex4 on
food intake and global c-fos reactivity. Study II aimed to investigate the
dose-response of Ex4. C57BL/6 J male mice were obtained from
Taconic (Denmark). At arrival the mice were single housed in a re-
versed 12 h/12 h daily rhythm with lights oﬀ at 11 am. The mice were
fed ad libitum a standard diet with 10% kcal fat (Research Diets
#D12450B, New Brunswick NJ, USA) and had free access to water.
Prior to study start, the mice were randomised into groups according to
body weight to minimize statistical variations between the groups. To
habituate and reduce the stress levels that are connected to acute s.c.
injection, the mice were handled mimicking injection and weighed
daily for 7 days prior to injection. The handling was performed by
pinching the mice in the neck between thumb and foreﬁnger. For all
experiments, food was removed 3 h prior to dark phase and given back
at the onset of dark. The mice were dosed s.c. 45min before onset of
dark and received two injections per experiment (n=8). Injection
volume per compound was 2.2ml/kg. The compounds were made at
Novo Nordisk A/S (Måløv, Denmark). PYY(3-36) was dissolved in 5mM
acetate, 250 nM glycerol, 0.05% tween 80, pH 4.0 and Ex4 was dis-
solved in 50mM phosphate, 70 nM NaCl, 0.05% tween 80, pH 7.4. For
study I, 32 mice aged 33weeks and weighing 29-39 g were included
(n= 8/group). For both the acute food intake and global brain c-fos
reactivity study, the vehicle dosed mice were dosed with vehicle buﬀers
for both PYY(3-36) and Ex4, mice in the PYY(3-36) group were dosed
with PYY(3-36) (200 μg/kg) and vehicle buﬀer for Ex4, mice in Ex4
group were dosed with Ex4 (2.5 μg/kg) and vehicle buﬀer for PYY(3-
36) and mice in the combination group were dosed with PYY(3-36)
(200 μg/kg) and Ex4 (2.5 μg/kg). For study II, 24 mice aged 10weeks
and weighing 24-29 g were included (n=8/group). The used doses for
dose-response of Ex4 were 2.5 μg/kg, 90 μg/kg, 170 μg/kg. The vehicle
dosed mice received vehicle buﬀers for both PYY(3-36) and Ex4, while
the Ex4 dosed mice received vehicle buﬀer for PYY(3-36).
2.3. Biodaq system for food intake measurement
Food intake was measured using a BioDaq system (Research Diets,
Inc. New Brunswick NJ, USA). The mice were acclimated for 7 days in
the BioDAQ system before acute food intake measurements in response
to the treatments. On the experimental day, food was removed from the
mice 3 h prior to dark phase and given back at the onset of dark. The
mice were s.c. injected 45min before onset of dark, and the access of
food was available at the onset of dark. The mice received two single
s.c. injections; either veh-PYY(3-36/veh-Ex4, PYY(3-36/veh-Ex4, Ex4/
veh-PYY(3-36) or PYY(3-36)/Ex4 (2.2 ml/kg). For the dose-response of
Ex4, the mice were also received two single s.c injections of either veh-
PYY(3-36)/veh-Ex4 or Ex4/veh-PYY(3-36) in the diﬀerent doses. Food
intake was measured during 22 h.
2.4. Global brain c-fos
The mice were handled mimicking injection and weighed daily for
11 days prior to injection. On the experimental day, food was removed
from the mice 3 h prior to dark phase and given back at the onset of
dark. The mice received two single s.c. injections 45min before onset of
dark phase; either veh-PYY(3-36)/veh-Ex4, PYY(3-36)/veh-4, Ex4/veh-
PYY(3-36) or PYY(3-36)/Ex4 (2.2 ml/kg). 1.5 h after dosing, the mice
were anesthetized with isoﬂuran followed by cardiac perfusion under
anaesthesia. The mice were perfused (30ml/min) with saline followed
by 4% paraformaldehyde (PFA). The brains were dissected and stored
in 4% PFA overnight at room temperature and transferred stepwise to
100% methanol in ddH2O (20% methanol for 1 h, 40% methanol for
1 h, 60% methanol for 1 h, 80% methanol for 1 h, and 100% methanol
for 1 h twice). For immunostaining with c-fos the iDISCO was per-
formed as described in (Salinas et al., 2018) with one exception: The
primary antibody was Rabbit-a-cfos (1:5000, cat. # 2250, Cell Signal-
ling), and incubation times for primary and secondary antibody were
extended to 7 days each.
2.5. Quantiﬁcation of c-fos reactivity
A cell segmentation algorithm was used prior to construction of c-
fos brain reactivity heat maps, which were then used for visualization
and quantiﬁcation. Quantiﬁcation was performed by summation of the
heat map intensity value of all voxels within the individual brain re-
gions, indicating the total brain activation signal in these regions. The
results were reported as fold change compared to the vehicle treated
group (further details, see (Jensen et al., 2018)). For details of brain
atlas and image registration, see reference (Jensen et al., 2018). How-
ever, the c-fos intensity for BST, CeA, rostral part of the mediobasal
ARH and compact DMH were calculated in deﬁned images in Allen
brain atlas. BST; image 49-52 (corresponding to bregma 0.50 to 0.14/
0.02 in Paxinos and Franklin's mouse brain atlas). CeA; image 68-74
(bregma −1.34 to −2.06). Rostral part of the mediobasal ARH; image
68-72 (bregma−1.58 to−1.70). Compact DMH; image 72–74 (bregma
−1.82 to −2.06).
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2.6. Statistics
Data obtained from the study were analyzed and associated graphs
were created in GraphPad Prism version 7.00 (GraphPad Software Inc.,
La Jolla, CA, USA). The statistical analysis of acute food intake and
selected c-fos brain areas (Supplemental Fig. 1) were performed by a
two sided ANOVA followed by a Tukeys's multiple comparisons test to
test for signiﬁcance between groups. c-fos heat map intensities were
analyzed using multiple t-tests assuming unequal variance. Statistical
signiﬁcance was determined by correcting for multiple comparisons by
a false discovery rate set to 10%. Total c-fos intensity is presented as
fold change relative to vehicle treated groups. Total c-fos intensity
(Supplemental Fig. 1) and acute food intake at 1.5 h after dosing are
presented as means ± standard errors of mean (SEM). A p-value of
0.05 or less was considered statistically signiﬁcant.
3. Results
3.1. Acute food intake and body weight change
The accumulated food intake over 22 h showed that PYY(3-36)
(200 μg/kg) and Ex4 (2.5 μg/kg) in combination resulted in reduced
food intake compared to vehicle and PYY(3-36) dosed mice until 10 h
after dosing (Fig. 1A). Mice treated with PYY(3-36) (200 μg/kg) only
reduced food intake until 2 h after dosing compared to vehicle, while
Ex4 (2.5 μg/kg) dosing reduced food intake compared to vehicle dosed
mice until 8 h after dosing (Fig. 1A). At 1.5 h after dosing, PYY(3-36)
and Ex4 in combination reduced food intake with approximately 100%
compared to vehicle (p < .0001), and also signiﬁcant reduced com-
pared to PYY(3-36) (p < .05) and Ex4 (p < .01). When subjected to
statistical evaluation of synergism, there was no statistical interaction/
synergistic eﬀect between PYY(3-36) and Ex4. A single administration
of either PYY(3-36) and Ex4 resulted in almost 50% reduction in food
intake compared to vehicle (p < .05, p < .01) (Fig. 1B). 24 h after
dosing, the mice treated with PYY(3-36) and Ex4 in combination had
the greatest change in body weight compared to vehicle and PYY(3-36)
treated mice (p < .001), while no diﬀerences were observed compared
to Ex4 (Fig. 1C). Based on the eﬀects on food intake at 1.5 h, it was
decided to investigate the brain c-fos reactivity 1.5 h after dosing. Dose
response of Ex4 was also tested to investigate if a higher dose of Ex4
could lower food intake to same extent as with the combination of PYY
(3-36) and Ex4, and this resulted in a dose-dependent reduction in food
intake (p < .05, p < .001) (Fig. 1D). However, the doses of Ex4 did
not lower food intake to the same extent as with PYY(3-36) and Ex4 in
combination (p < .001, p < .05) (Fig. 1B & D).
3.2. Acute global brain c-fos reactivity
Mice treated with PYY(3-36) showed no signiﬁcant increase in c-fos
immunoreactivity compared to the vehicle treated mice (Supplemental
Fig. 1A & Fig. 3), while mice treated with Ex4 had enhanced c-fos re-
activity in 9 brain regions compared to vehicle including central
amygdalar nucleus (CeA), the lateral hypothalamic area (LHA), the
parasubthalamic nucleus (PSTN), the paraventricular thalamus (PVT),
locus ceruleus (LC), area postrema (AP), cuneate nucleus (CU), dorsal
motor nucleus of the vagus nerve (DMX) and the nucleus of the solitary
tract (NTS) (Supplemental Fig. 1B & Fig. 3). When combining PYY(3-
36) and Ex4, a total of 25 brain regions were signiﬁcantly upregulated
in c-fos immunoreactivity compared to vehicle treated mice. The acti-
vation of c-fos was evident in the same regions as with Ex4 individually,
but to a signiﬁcantly greater extend and additional 16 regions were
positive for c-fos in the combination group. The additional 16 brain
regions included the bed nucleus of striatum (BST), arcuate hypotha-
lamus nucleus (ARH), the dorsomedial nucleus of the hypothalamus
(DMH), lateral preoptic area (LPO), median eminence (ME), medial
mammilary nucleus (MM), periventricular hypothalamic nucleus, pos-
terior part (PVp), tuberal nucleus (TU), ventromedial hypothalamic
nucleus (VMH), lateral habenula (LH), ventral tregmental area (VTA),
parabrachial nucleus (PB), pontine central gray (PCG), supratrigeminal
nucleus (SUT), and the lateral reticular nucleus, magnocellular part
(LRNm) (Supplemental Fig. 1C & Fig. 3). Within CeA, rostral medio-
basal ARH, PB, SUT, AP, and NTS an interaction between PYY(3-36)
and Ex4 was furthermore responsible for the c-fos signal, suggesting a
synergistic eﬀect in neuronal activation. The c-fos signal intensities in
each brain region were compared between the group receiving the PYY
(3-36) and Ex4 in combination and the group receiving Ex4, to illustrate
the diﬀerences in neuronal activation between those two groups
(Fig. 2). Seven regions in the PYY(3-36) and Ex4 group displayed a
signiﬁcantly increase in c-fos response compared to Ex4 individually
namely the CeA, rostral part of the mediobasal ARH, SUT, PB, AP, NTS
and LRNm (Figs. 2 and 3). In Supplemental Fig. 2, examples of com-
paring images of c-fos nucleus with heat map of c-fos intensity in PB
and AP/NTS for the diﬀerent groups are illustrated.
4. Discussion
The present study demonstrated global activation of c-fos in the
brain following administration of PYY(3-36) and Ex4 in combination.
Fig. 1. Food intake and body weight change after a single s.c. injection of PYY(3-36) and Ex4 and the combination thereof: A) Acute accumulated food intake
(0−22 h), B) Acute food intake 1.5 h after dosing, C) 24 h body weight change after dosing, D) Dose response of Ex4 on food intake 1.5 h after dosing. Data are
expressed as means ± SEM, n=6–8, analyzed by two sided ANOVA followed by a Tukeys's multiple comparisons test to test for signiﬁcance between groups. In
Fig. 1A, “a” indicates signiﬁcant diﬀerences between vehicle and PYY(3-36), “b” signiﬁcant diﬀerences between vehicle and Ex4, “c1” signiﬁcant diﬀerences between
vehicle and PYY(3-36) and Ex4 combination, “c2” signiﬁcant diﬀerences between PYY(3-36) and PYY(3-36) and Ex4 combination, “c3” signiﬁcant diﬀerences
between Ex4 and PYY(3-36) and Ex4. In Fig. 1B–D, “1” indicates signiﬁcant diﬀerences to the vehicle, “2” signiﬁcant diﬀerences to PYY(3-36), “3” signiﬁcant
diﬀerences to Ex4. (p < .05*, p < .01**, p < .001***).
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We show that the additive reduction in food intake 1.5 h after co-dosing
with PYY(3-36) and Ex4 is associated with synergistic enhanced c-fos
reactivity in CeA, rostral part of the mediobasal ARH, SUT, PB, AP, NTS,
and LRNm compared to vehicle, PYY(3-36) and Ex4 dosed mice. Many
neurons express the immediate-early gene c-fos when activated and this
protein has been considered as a robust marker to study neuronal ac-
tivity (Morgan & Curran, 1991). However, c-fos is not a global marker
and we are aware that not all neuronal activity was captured. Hence,
there may be additional diﬀerences in brain activation and inhibition
which were not captured by this method. To ensure an acute additive/
synergistic eﬀect of the PYY(3-36) and Ex4, acute food intake was
measured prior to the c-fos analysis. The brain regions activated by PYY
(3-36) and Ex4 in combination resembled the regions activated by Ex4
individually, but with a signiﬁcantly stronger c-fos response and with
more regions signiﬁcantly aﬀected in the combination group (Supple-
mental Fig. 1). PYY(3-36) has been demonstrated to have an inhibitory
eﬀect on neurons (Batterham et al., 2002; Riediger et al., 2004) and no
remarkable increase in c-fos reactivity was observed with PYY(3-36)
alone compared to vehicle dosed mice. Thus, the synergistic activation
of c-fos, indicates that PYY(3-36) in combination with Ex4 boosts the
eﬀect of Ex4, which could be through input from vagus nerve and
disinhibition of Ex4 induced neuronal activity.
It could be speculated whether the observed c-fos reactivity was
induced by fasting as the mice dosed with PYY(3-36) and Ex4 in com-
bination only consumed 0,04 g of food which nearly resemble a fasting
condition. However, in a previous study, fasted mice (fasted during
light phase as in the present study), no c-fos reactivity was observed in
AP and NTS (Riediger et al., 2004) in contrast to the present study
results. In addition, mice dosed with either PYY(3-36) or Ex4 in-
dividually, consumed approximately the same amount of food and the
c-fos reactivity in these two groups was also diﬀerent suggesting an
interaction of the combination treatment rather that fasting. Further-
more, the massive suppression in food intake appears to be speciﬁc for
PYY(3-36) and Ex4 in combination as a 68 times higher dose of Ex4
(170 μg/kg) alone compared to the Ex4 (2.5 μg/kg) dose could not
lower the appetite to the same extent (Fig. 1B & D). This could be in-
terpreted as follows: the high Ex4 dose alone is not suﬃcient to lower
food intake but needs additional activation of non GLP-1R neuron po-
pulations to further lower the food intake. The high Ex4 dose (170 μg/
kg) may induce a counter-regulatory response to avoid a marked re-
duction in appetite, and PYY(3-36) may ameliorate this eﬀect poten-
tially through disinhibition of the same areas. However, as no prior
scientiﬁc evidence for a counter-regulatory response has been shown,
this remains speculative. The enhanced c-fos reactivity could also be
induced by several additional mechanisms such as 1) an increased ac-
cess of PYY(3-36) and Ex4 into brain (Salinas et al., 2018; Kastin &
Akerstrom, 2003; Kastin et al., 2002; Nonaka et al., 2003), 2) increased
interaction of appetite-regulating neurons and cross talk between dif-
ferent regions of the brain (Sohn et al., 2013; Carter et al., 2013), and 3)
increased input from vagus nerve (Koda et al., 2005; Egerod et al.,
2018; Iwasaki et al., 2013; Kakei et al., 2002). Hence, recruitment of
diﬀerent signalling pathways within and to the brain by PYY(3-36) and
Ex4 may contribute to their additive/synergistic action. It is well de-
monstrated that the anorexigenic eﬀect of PYY(3-36) is mediated both
through activating the vagal aﬀerent (Koda et al., 2005; Iwasaki et al.,
2013) and through inhibition of the orexigenic AgRP/NPY neurons in
ARH (Batterham & Bloom, 2003; Shi et al., 2013). AgRP/NPY neurons
co-express GABA which antagonizes several neurons such as the CART/
POMC neurons in the ARH (Secher et al., 2014), the CGRP neurons in
the PB (Wu et al., 2009), neurons in the BST (Betley et al., 2013) and
PVH neurons via Y1 receptors and AgRP inhibiting the MC4R (Cone,
2005). For GLP-1, the acute anorectic eﬀect is also mediated through
activation of the vagal aﬀerent (Kakei et al., 2002) and in ARH through
activation of POMC/CART neurons and a simultaneous indirect GA-
BAergic inhibition of the AgRP/NPY neurons (Secher et al., 2014; Barsh
& Schwartz, 2002). The enhanced c-fos in the rostral part of the med-
iobasal ARH (and PVp) was interesting as it contains a large population
of AgRP/NPY and POMC/CART neurons (Broberger et al., 1997). In-
creased POMC/CART activity due to reduced inhibition from AgRP/
NPY neurons together with GLP-1R binding of Ex4 on the POMC/CART
neurons may reﬂect the increased c-fos in ARH and PVp (Batterham
et al., 2002; Challis et al., 2003). Some research groups have observed
increased c-fos reactivity with PYY(3-36) individually in diﬀerent brain
regions such as BST, CeA, ARH, PB, AP, NTS (Koda et al., 2005;
Fig. 2. Comparison of average c-fos signal intensities in each brain region between the PYY(3-36) and Ex4 in combination and the Ex4 group. Scatter plot of summed
heat map signal in brain regions with Ex4 values (y-axis) plotted against PYY3-36+Ex4 (x-axis). The graph to the right is a close-up of the graph to the left. Only
regions that were signiﬁcant diﬀerent between PYY(3-36) and Ex4 and Ex4 individually are marked. The regions that displayed a signiﬁcantly increase in c-fos
response in the PYY(3-36) and Ex4 group compared to Ex4 individually were CeA, rostral part of the mediobasal ARH, SUT, PB, AP, NTS and LRNm (see also
Supplemental Fig. 1). Data, n= 6–8, are analyzed by two sided ANOVA followed by a Tukeys's multiple comparisons test to test for signiﬁcance between groups.
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Batterham et al., 2002; Baraboi et al., 2010; Halatchev et al., 2004).
This could be related to a higher dose of PYY(3-36) and thus indirect c-
fos induction as shown with POMC because of less GABAergic
inhibition from NPY/AgRP neurons (Batterham et al., 2002; Challis
et al., 2003). Moreover, NPY neurons are widely expressed in both
hypothalamus and hindbrain, and a large population of these may also
Fig. 3. Total c-fos signal in selected brain regions (selected from comparison of average c-fos signal intensities (Fig. 2) and heat maps (Supplemental Fig. 1)). Note the
diﬀerences in y-axes. For quantiﬁcation of c-fos reactivity, a cell segmentation algorithm was used prior to construction of c-fos brain reactivity heat maps, which
were then used for visualization and quantiﬁcation (for further details, see methodology section). Bed nucleus of striatum (BST), central amygdalar nucleus (CeA),
paraventricular thalamus (PVT), parasubthalamic nucleus (PSTN), periventricular hypothalamus (PVH), median eminence (ME), arcuate hypothalamus nucleus
(ARH), periventricular hypothalamic nucleus, posterior part (PVp), the dorsomedial nucleus of the hypothalamus (DMH), ventromedial hypothalamic nucleus
(VMH), the lateral hypothalamic area (LHA), parabrachial nucleus (PB), supratrigeminal nucleus (SUT), lateral reticular nucleus, magnocellular part (LRNm) area
postrema (AP), nucleus of the solitary tract (NTS), dorsal motor nucleus of the vagus nerve (DMX). “1” indicates signiﬁcant diﬀerences to the vehicle, “2” signiﬁcant
diﬀerences to PYY(3-36), “3” signiﬁcant diﬀerences to Ex4. (p < .05*, p < .01**, p < .001***).
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express the Y2 receptor as shown for ARH (Broberger et al., 1997).
Thus, NPY or Y2 positive neurons in several brain regions could be
inhibited by direct PYY(3-36) binding of Y2 allowing for additional
GLP-1R signalling to occur in secondary brain regions.
Furthermore, the hindbrain showed strong neuronal activity.
Recently, Egerod and colleagues demonstrated that GLP-1R and Y2
were expressed in vagal aﬀerents, both co-expressed with cholecysto-
kinin receptor 1 (CCK1R) which may also be important for the synergy
of PYY(3-36) and Ex4 (Egerod et al., 2018) and the observed synergistic
c-fos reactivity in the hindbrain. For appetite reduction, the AP/NTS to
PB signalling pathway has been suggested with several appetite redu-
cing compounds such as GLP-1 analogues (Salinas et al., 2018; Swick
et al., 2015; Baraboi et al., 2011; Rowland et al., 1997), amylin
(Rowland et al., 1997; Lutz, 2005), CCK-8 (Li & Rowland, 1995) and in
mice with RYGB (Mumphrey et al., 2016). The PB receives and in-
tegrates neuronal input from various brain regions, especially the hy-
pothalamus and hindbrain (Carter et al., 2013; Tokita et al., 2009;
Papas & Ferguson, 1990). For control of appetite and blood glucose,
neurons in the PB project to CeA and BST (Carter et al., 2013; Meek
et al., 2016; Campos et al., 2016). In the present study, two clusters of
signiﬁcantly increased c-fos reactivity were found in the PB for PYY(3-
36) and Ex4 in combination which were not observed for PYY(3-36) or
Ex4 individually. CGRP neuron expression is characteristic to PB and
mediates appetite reduction through innervation of CeA (Mumphrey
et al., 2016). In the RYGB mice c-fos reactivity was co-expressed with
CGRP neurons in PB (Mumphrey et al., 2016) and this may also be the
case in the present study. RYGB is associated with an increased post-
prandial response of PYY(3-36) and GLP-1 in humans (Le Roux et al.,
2006; Dirksen et al., 2013) and in rats exposed to ileal transposition
(Strader et al., 2005). The increase in PYY(3-36) and GLP-1 may con-
tribute to c-fos reactivity induced in the NTS to PB to CeA pathway
demonstrated by Mumphrey and colleagues (Mumphrey et al., 2016) as
well as in the present study. The CGRP neurons in the PB can be acti-
vated by diﬀerent pathways of which the most studied are by an re-
duction of the tonus of the hypothalamic NPY/AgRP neurons (Wu et al.,
2009) as well as increased POMC/CART activity and by glutamatergic
innervation from hindbrain (van der Kooy & Koda, 1983). For the sy-
nergistic eﬀect of PYY(3-36) and Ex4, all pathways may have con-
tributed to the increased activation of neurons in the PB. We also ob-
served signiﬁcant c-fos reactivity in CeA and BST in the combination
group. The CGRP neurons are demonstrated to project to CeA and may
contribute to this. In BST the enhanced c-fos may also be caused by a
reduced tonus of the NPY/AgRP neurons (Betley et al., 2013) together
with increased input from CeA (Carter et al., 2013). The c-fos activated
pathways in the present study support previous studies showing that
appetite reduction involves AP/NTS to PB to CeA neuronal circuits.
Interestingly, activation of brain regions such as LRNm and SUT was
novel and speciﬁc for the combination group. To our knowledge, LRNm
and SUT have not been described to be associated with regulation of
energy balance, but appear to be involved in jaw movements which
could be related to the initiation of eating (Fujio et al., 2016;
Alstermark & Ekerot, 2013). Furthermore, according to Allen brain
atlas the brain area SUT sends neuronal projections to PB in normal
C57BL/6 J mice, indicating a potential interaction between PB and SUT
which may be induced by PYY(3-36) and Ex4 in combination. The
LRNm appears to regulate several functions as it provides the cere-
bellum with signals to control posture, reaching, grasping, locomotion,
scratching and respiration (Alstermark & Ekerot, 2013; Xu et al., 2013),
involvement in pain (Ossipov & Gebhart, 1986) and regulation of heart
rate and blood pressure in cats (Thomas et al., 1977). A viral-genetic
tracing study has also demonstrated that LRNm project to locus cer-
uleus (LC) (Schwarz et al., 2015) a brain region known to be involved in
arousal and attention and recently also in reward processing in mon-
keys (Bouret & Richmond, 2015). In the present study, increased c-fos
reactivity was observed in LC, but this was also observed with Ex4.
Thus, the observed enhancement of c-fos response in SUT and LRNm
needs further investigation to understand if the regions contributed to
the additive/synergistic eﬀect of PYY(3-36) and Ex4 on food intake.
In conclusion, the present study demonstrated global brain c-fos
reactivity in mice treated with PYY(3-36) and Ex4 in combination. The
additive reduction in food intake by PYY(3-36) and Ex4 was associated
with synergistic enhanced c-fos reactivity in the rostral part of the
mediobasal ARH and the appetite-reducing AP/NTS to PB to CeA
pathway. The combination of PYY(3-36) and Ex4 also activated LRNm
and SUT which has not previously been reported in the regulation of
energy homeostasis. In addition to appetite reduction, the signiﬁcant
increase in c-fos reactivity may also contribute to regulation of other
biological responses that are not investigated in the present study. As
PYY(3-36) and Ex4 act on diﬀerent neurons leading to recruitment of
diﬀerent signalling pathways within and to the brain, an interaction of
these pathways may contribute to their additive/synergistic action.
Thus, PYY(3-36) boosts the eﬀect of Ex4 possibly by inducing less in-
hibition of neuronal activity leading to an enhanced neuronal activity
induced by Ex4.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.npep.2018.11.004.
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